About Miles of Smiles
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood, adolescent and young adults. Clinically, survival among metastatic RMS patients has remained unacceptably low and unimproved for years-- several decades, actually. The most aggressive type of RMS is Alveolar Rhabdomyosarcoma (ARMS). ARMS has received very little clinical research and deserves more attention. It is unacceptable that no new agents have emerged for testing in clinical trials for high-risk or relapsed RMS patients in the last 6 years. As a result, the disease-free survival for ARMS has remained unchanged for 47 years! It is disheartening to know that NO primary drug approvals for RMS have occurred in history EVER...and only 8 drugs developed for any childhood cancer have been FDA approved since 1978. By comparison, 12 or more adult cancer drugs, on average, are FDA approved annually. cc-TDI is bringing new and exciting innovations and recent discoveries to the specific challenges posed by RMS. The Ramirez Family is raising critical funding for one of cc-TDI's most promising research projects, in honor of their smiley, brave little guy, Miles. The goal is to raise $180,000 for pre-clinical testing of a drug called Entinostat. This drug has shown tremendous promise in the cc-TDI labs as a potential treatment that could restore chemotherapy sensitivity and thereby improve outcomes for RMS patients. With this amount of funding, it will pay for the pre-clinical testing of Entinostat which will increase the likelihood that a full clinical trial will be approved. Kids like Miles who have fought RMS need hope. Getting this clinical trial funded will be a much needed dose of hope that these kids and their families desperately need. Please support The Ramirez family as they seek to raise funding for research that will affect real change for all of the brave kids, like Miles.
